Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combination with obinutuzumab) or for patients with relapsed/refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Waggoner, Matthew, Katsetos, John, Thomas, Emilee, Galinsky, Ilene, Fox, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214960/
https://www.ncbi.nlm.nih.gov/pubmed/35755897
http://dx.doi.org/10.6004/jadpro.2022.13.4.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214960/
https://www.ncbi.nlm.nih.gov/pubmed/35755897
http://dx.doi.org/10.6004/jadpro.2022.13.4.4

Ejemplares similares